Neutralizing Antibody For Treatment Of COVID-19

Early Treatment / Prevention Features Reduces progression rates to severe COVID-19 in mild-to-moderate patients Decreases hospitalization rate ($73,300 cost) and oxygen therapy use ($550,000 cost) Shortens the time to clinical recovery Molecule: Recombinant human IgG1 lambda antibody directed against SARS-CoV-2 receptor binding domain (RBD) Authorized use: mild to moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. Vial & dosage: 960mg per 24kg Approvals: EMA (European Medicines Agency), FDA EUA (pending) Korea EUR (approved) MOQ: 10,000 vials (960mg, 16ml) FOB Korea: €650 (commission included) MSRP: €960~€1,920 Lead time: 60~90 days Production capacity: 200,000 vials per month